Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
23 mars 2023 03h00 HE
|
Anaveon
BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
16 mars 2023 03h00 HE
|
Anaveon
BASEL, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study - a...
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
02 févr. 2023 02h00 HE
|
Anaveon
BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
10 sept. 2022 03h00 HE
|
Anaveon
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
08 avr. 2022 13h00 HE
|
Anaveon
- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
Anaveon to raise CHF 110 million in oversubscribed Series B financing
16 déc. 2021 02h00 HE
|
Anaveon
- Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...